Fig. 3: Intervention with fission/fusion balance differentially affects BM-MSCs bioenergetics, mtROS and ΔΨm.
From: Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target
ND (cyan) and MM (red) MSCs (n≧3) were treated with Mdivi-1 (mitochondrial fission inhibitor, 50 µM; 24 h), MYLS22 (mitochondrial fusion inhibitor, 50 µM; 24 h), M1 (mitochondrial fusion promoter, 5 µM; 24 h), Ascorbic Acid (AA) (ROS scavenger, 500 µM; 24 h) and analyzed for (A) MM-MSCs glycoATP, mitoATP and TotalATP production rates following Mdivi-1 treatment (Seahorse XF Real-Time ATP Rate Assay Kit) (B) MM-MSCs SRC following Mdivi-1 treatment (Seahorse XF Cell Mito Stress Test Kit). C ND-MSCs glycoATP, mitoATP and TotalATP production rates following MYLS22 treatment (Seahorse XF Real-Time ATP Rate Assay). D ND-MSCs SRC following MYLS22 treatment (Seahorse XF Cell Mito Stress Test Kit). E ND and MM-MSCs mtROS levels following MYLS22 treatment (mitoSOX red). F MM-MSCs mitochondrial membrane potential following MYLS22 treatment (TMRE). G MM-MSCs mitochondrial membrane potential following AA treatment (TMRE). H ND-MSCs mitochondrial membrane potential following M1 treatment (TMRE). I ND-MSCs mtROS levels following M1 treatment (mitoSOX red). J ND-MSCs proton leak following Mdivi-1/MYLS22 treatment (Seahorse XF Cell Mito Stress Test Kit). Results are expressed as percentage (Mean ± SE, n ≥ 3) and normalized to untreated cells represented by control bar (100%) or dashed line. Asterisks depicted statistical significance *p < 0.05; **p < 0.01.
